Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents

Am J Hematol. 2020 Jul;95(7):792-798. doi: 10.1002/ajh.25808. Epub 2020 May 4.

Abstract

Invasive fungal infections (IFI) are a significant source of morbidity and mortality for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Given the heterogeneity of the population receiving hypomethylating agents (HMA), it is difficult for clinicians to accurately assess their patients' risk of infection. Literature on the incidence of IFI following HMA is limited to several studies of azacitidine. The primary objective of this retrospective study was to establish the incidence of IFI in HMA treated AML/MDS patients at a large U.S. comprehensive cancer center. Secondary objectives included comparing incidence of IFI among pre-specified subgroups to identify potential risk factors for IFI. Two hundred three patients with AML, intermediate to very high risk MDS or chronic myelomonocytic leukemia who received at least two cycles of HMA were included. The incidence of IFI, as defined by the European Organization for Research and Treatment of Cancer / Invasive Fungal Infections Cooperative Group criteria, was 9.6%, with 20 IFI diagnosed following HMA (three proven, four probable, 13 possible). Among the proven cases of IFI, molds included Scedosporium and Fusarium spp. Eleven patients who developed IFIs were neutropenic upon initiating HMA. The majority (17/20) of infections occurred during the first four cycles. Given this incidence, mold-active prophylaxis can be considered in patients who are neutropenic at the start of therapy.

MeSH terms

  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Female
  • Fusariosis* / chemically induced
  • Fusariosis* / epidemiology
  • Fusariosis* / prevention & control
  • Fusarium*
  • Humans
  • Incidence
  • Invasive Fungal Infections* / chemically induced
  • Invasive Fungal Infections* / epidemiology
  • Invasive Fungal Infections* / prevention & control
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / epidemiology
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes* / drug therapy
  • Myelodysplastic Syndromes* / epidemiology
  • Retrospective Studies
  • Risk Factors
  • Scedosporium*

Substances

  • Antineoplastic Agents

Supplementary concepts

  • scedosporiosis